Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- BONEX.ST
- Price
- 291.60
- Stock movement down
- -7.00 (-2.34%)
- Company name
- Bonesupport Holding AB
- Exchange
- (ST ,
- Currency
- SEK )
- Sector
- Healthcare >Medical Instruments & Supplies
- Market cap
- 19.20B
- Ent value
- 19.17B
- Price/Sales
- 23.58
- Price/Book
- 29.02
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- 212.03
- Forward P/E
- 62.94
- PEG
- -
- EPS growth
- -
- 1 year return
- 22.11%
- 3 year return
- 88.90%
- 5 year return
- 57.07%
- 10 year return
- -
Last updated: 2025-04-12
DIVIDENDS
BONEX.ST does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | 212.03 |
| Price to OCF | 3572.27 |
| Price to FCF | - |
| Price to EBITDA | 165.37 |
| EV to EBITDA | 165.06 |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 23.58 |
| Price to Book | 29.02 |
| EV to Sales | 23.53 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 65.86M |
| EPS (TTM) | 1.36 |
| FCF per share (TTM) | -0.05 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 814.46M |
| Gross profit (TTM) | 752.82M |
| Operating income (TTM) | 106.68M |
| Net income (TTM) | 90.58M |
| EPS (TTM) | 1.36 |
| EPS (1y forward) | 4.63 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 92.43% |
| Operating margin (TTM) | 13.10% |
| Profit margin (TTM) | 11.12% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 153.16M |
| Net receivables | 177.57M |
| Total current assets | 511.94M |
| Goodwill | 0.00 |
| Intangible assets | 14.20M |
| Property, plant and equipment | 0.00 |
| Total assets | 778.65M |
| Accounts payable | 10.41M |
| Short/Current long term debt | 14.99M |
| Total current liabilities | 107.94M |
| Total liabilities | 116.85M |
| Shareholder's equity | 661.80M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | 5.38M |
| Capital expenditures (TTM) | 8.46M |
| Free cash flow (TTM) | -3.09M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | 13.69% |
| Return on Assets | 11.63% |
| Return on Invested Capital | 13.55% |
| Cash Return on Invested Capital | -0.46% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 296.00 |
| Daily high | 296.80 |
| Daily low | 278.80 |
| Daily Volume | 203K |
| All-time high | 400.20 |
| 1y analyst estimate | 402.33 |
| Beta | 0.97 |
| EPS (TTM) | 1.36 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 23 Apr 2025 |
Downside potential
Loading...
Downside potential data
| BONEX.ST | S&P500 | |
| Current price drop from All-time high | -27.14% | -12.89% |
| Highest price drop | -69.77% | -56.47% |
| Date of highest drop | 12 Jun 2018 | 9 Mar 2009 |
| Avg drop from high | -19.51% | -11.07% |
| Avg time to new high | 12 days | 12 days |
| Max time to new high | 479 days | 1805 days |
COMPANY DETAILS
Marketcap
19.20B
Marketcap category
Large-cap
Description
Bonesupport Holding AB (publ), an orthobiologics company, develops and commercializes injectable bio-ceramic bone graft substitutes in Europe, North America, and internationally. The company provides CERAMENT Bone Void Filler, an injectable ceramic bone graft substitute that remodels to host bone; CERAMENT G, an injectable ceramic bone graft substitute that remodels to host bone and elutes Gentamicin during the critical first 30 days of bone healing, as well as treats and prevents bone infection; CERAMENT V, an injectable ceramic bone graft substitute that remodels to host bone and elutes Vancomycin during the critical first 30 days of bone healing, as well as treats and prevents bone infection. It also offers CERAMENT Bead Tray, an adjunctive local delivery option for surgeons for targeted delivery to osseous defects and for dead space management. In addition, the company develops preclinical product candidates to promote bone regrowth focusing on trauma, revision arthroplasty, chronic osteomyelitis, and foot and ankle surgery. The company was founded in 1999 and is headquartered in Lund, Sweden.
Employees
131
Website
Investor relations
-
SEC filings
CEO
Country
Sweden
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
No events found
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
The European market has faced a challenging week, with the pan-European STOXX Europe 600 Index declining by about 1.4% amid fresh U.S. trade tariffs and mixed economic signals, such as an expanding pr...
April 2, 2025
As the pan-European STOXX Europe 600 Index ended higher, breaking a streak of losses, investors are cautiously optimistic amid mixed signals from global economic policies and trade tensions. In this e...
March 24, 2025
As European markets navigate a landscape marked by mixed economic signals and trade-related uncertainties, the pan-European STOXX Europe 600 Index has managed to break a two-week losing streak, buoyed...
March 24, 2025
The European market has been experiencing a positive streak, with the pan-European STOXX Europe 600 Index posting its longest series of weekly gains since August 2012, driven by encouraging company re...
March 4, 2025
In February 2025, global markets are experiencing a mix of optimism and caution, with U.S. stock indexes nearing record highs amid an environment of accelerating inflation and uncertain trade policies...
February 21, 2025
As global markets navigate a complex landscape marked by fluctuating economic indicators and competitive pressures in the technology sector, investors are closely watching key indices like the Nasdaq ...
February 3, 2025
As global markets experience a boost from cooling inflation and robust bank earnings, value stocks have notably outperformed growth shares, particularly in the U.S. This environment presents an opport...
January 23, 2025
As we step into January 2025, global markets are witnessing a mixed sentiment with U.S. consumer confidence on the decline and key indices such as the Nasdaq Composite showing moderate gains amidst a ...
January 2, 2025
In the current global market landscape, characterized by cautious Federal Reserve commentary and political uncertainties, investors are navigating through a period of volatility. Despite these challen...
December 25, 2024
As global markets continue to reach new heights, with small-cap indices like the Russell 2000 hitting record intraday highs, investor sentiment is buoyed by domestic policy developments and strong con...
December 4, 2024
Next page